Understand the source comparison
ARA-290 Blood Work Labs Check Before After Comparison
Before writing any comparison table in this article, this sentence confirms what the table will show and why it matters: the table below compares required lab panels, timing, and interpretation thresholds across the three critical checkpoints in an ARA-290 res
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Before writing any comparison table in this article, this sentence confirms what the table will show and why it matters: the table below compares required lab panels, timing, and interpretation thresholds across the three critical checkpoints in an ARA-290 research protocol.
- High-Sensitivity CRP (hs-CRP)
- Required. Ideal baseline 3.0–10.0 mg/L for measurable effect
- Expected 15–30% reduction from baseline
- Expected 30–50% reduction from baseline if protocol effective
- Most critical biomarker for tracking ARA-290's anti-inflammatory mechanism. Baseline below 1.0 mg/L yields minimal observable delta
- Cytokine Panel (IL-6, TNF-alpha, IL-1beta)
- Required. Establishes pro-inflammatory baseline
- IL-6 should decline 20–35% if pathway engagement occurring
- Sustained reduction or further decline confirms pathway remains active
- Pro-inflammatory cytokines are the direct mechanistic target. Reductions here prove IRR pathway activation
- Complete Metabolic Panel (CMP)
- Required. Creatinine and eGFR must be normal (eGFR >60 mL/min)
- Monitor creatinine stability. Should remain within 10% of baseline
- Confirm renal function unchanged. Creatinine elevation >0.3 mg/dL warrants investigation
- Renal clearance pathway means impaired kidney function requires dose adjustment
- Complete Blood Count (CBC)
- Required. Confirms baseline hemoglobin/hematocrit in normal range
- Hemoglobin should remain stable (±0.5 g/dL from baseline)
- Any increase >1.0 g/dL suggests peptide contamination or unrelated erythropoiesis
- ARA-290 should NOT stimulate RBC production. Hemoglobin elevation is a red flag
- Baseline Erythropoietin (EPO) Level
- Required. Optimal baseline <15 mIU/mL for maximum observable effect
- Not typically repeated unless baseline was elevated
- Optional repeat if baseline EPO was >20 mIU/mL to track endogenous signaling
- Elevated baseline EPO suggests endogenous repair signaling already active, which may blunt exogenous peptide response
- Hemoglobin A1C (optional metabolic marker)
- Optional. Useful if studying metabolic/glycemic effects of ARA-290
- Not typically repeated at week 4
- Repeat at week 12 if baseline was elevated (>5.7%)
- Some protocols study ARA-290's effect on insulin sensitivity and glycemic control in metabolic syndrome subjects